Literature DB >> 7778128

Medium molecular weight factor X activating enzyme from Vipera berus berus venom.

M Samel1, J Siigur.   

Abstract

Vipera berus berus venom contains several factor X activating enzymes. One of them (VBFXAE) was separated by gel-filtration on Sephadex G-100 superfine and on a bacitracin-agarose column. The enzyme is a single-chain glycoprotein with mol. wt 38,000. The enzyme has several molecular forms with pI 3.5-4.5. After neuraminidase treatment the enzyme has pI 4.5. VBFXAE contains 2 Ca per mole. The activator is inactive on synthetic substrates, on casein, prothrombin, and fibrinogen, and appears to act specifically on factor X. The activator also weakly hydrolyses the insulin B-chain at the positions Ala14-Leu15 and Tyr16-Leu17. The cleavage of the insulin B-chain is inhibited by EDTA, suggesting the metalloproteinase nature of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7778128     DOI: 10.1016/0041-0101(94)00143-v

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  4 in total

1.  Comparative study of anticoagulant and procoagulant properties of 28 snake venoms from families Elapidae, Viperidae, and purified Russell's viper venom-factor X activator (RVV-X).

Authors:  Montamas Suntravat; Issarang Nuchprayoon; John C Pérez
Journal:  Toxicon       Date:  2010-09-15       Impact factor: 3.033

Review 2.  Biochemistry and toxicology of proteins and peptides purified from the venom of Vipera berus berus.

Authors:  Jüri Siigur; Ene Siigur
Journal:  Toxicon X       Date:  2022-06-12

3.  Persistent hypercoagulability in dogs envenomated by the European adder (Vipera berus berus).

Authors:  Hannah J Harjen; Marit Hellum; Runa Rørtveit; Malin Oscarson; Kristin P Anfinsen; Elena R Moldal; Susanna Solbak; Sandip M Kanse; Carola E Henriksson
Journal:  PLoS One       Date:  2022-02-18       Impact factor: 3.240

4.  Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors.

Authors:  Abhinandan Chowdhury; Christina N Zdenek; Matthew R Lewin; Rebecca Carter; Tomaž Jagar; Erika Ostanek; Hannah Harjen; Matt Aldridge; Raul Soria; Grace Haw; Bryan G Fry
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.